Sponsor

Pfizer Inc.

United States 66 Hudson Boulevard East, 10001-2189, United States

About the sponsor

Breast cancer, non-small cell lung cancer, small cell lung cancer, prostate cancer, and colorectal cancer are central areas of interest, alongside studies in ovarian cancer, head and neck squamous cell carcinoma, esophageal cancer, hepatocellular carcinoma, and bladder cancer. Research also extends to blood cancers such as multiple myeloma, diffuse large B-cell lymphoma, follicular lymphoma, acute lymphoblastic leukemia, and advanced lymphomas.

HER2-negative and hormone receptor-positive breast cancer
Advanced solid tumors
Relapsed or refractory multiple myeloma
Diffuse large B-cell lymphoma
Metastatic castration-resistant prostate cancer

Additional oncology work includes melanoma, non-muscle invasive bladder cancer, liposarcoma, and neuroblastoma, with a strong emphasis on advanced and metastatic disease settings.

About Specializations

Pfizer Inc. runs clinical trials in conditions such as Breast cancer, Alopecia areata, Non-small cell lung cancer, Breast cancer metastatic, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

126 clinical trials

Chronic obstructive pulmonary disease

Recruiting

Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Investigational

Study of PF-07275315 versus placebo for efficacy and safety in adults with moderate-to-severe chronic obstructive pulmonary disease (COPD)

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Sponsor:Pfizer Inc.

Contact Research Centre

Chronic spontaneous urticaria

Recruiting

A study to evaluate the effectiveness and safety of ritlecitinib tosilate and loratadine in adults with chronic spontaneous urticaria (hives)

Registered drug

A study to evaluate the effectiveness and safety of ritlecitinib tosilate and loratadine in adults with chronic spontaneous urticaria (hives)

Registered drug

Bulgaria

Participants:18–64 years · 65+ years
Substances:Loratadine
Sponsor:Pfizer Inc.

Contact Research Centre

Cardiac failure

Recruiting

Study of PF-07328948 tablets compared to placebo in adults with heart failure to evaluate effects on symptoms and physical function

Investigational

Study of PF-07328948 tablets compared to placebo in adults with heart failure to evaluate effects on symptoms and physical function

Investigational

Bulgaria

Participants:18–64 years · 65+ years
Substances:PF-07328948
Sponsor:Pfizer Inc.

Contact Research Centre

Dermatitis atopic

Recruiting

Study of abrocitinib oral suspension for children aged 2 years and older with moderate to severe atopic dermatitis to evaluate long-term safety and effectiveness

InvestigationalNo placebo

Study of abrocitinib oral suspension for children aged 2 years and older with moderate to severe atopic dermatitis to evaluate long-term safety and effectiveness

InvestigationalNo placebo

Germany

Participants:0–17 years
Substances:Abrocitinib
Sponsor:Pfizer Inc.

Contact Research Centre

Respiratory syncytial virus immunisation

Recruiting

Safety, Tolerability and Immunogenicity of RSV prefusion F protein 847a and 847b Vaccine in Children 5‑17 Years at High Risk of RSV Disease

Registered drug

Safety, Tolerability and Immunogenicity of RSV prefusion F protein 847a and 847b Vaccine in Children 5‑17 Years at High Risk of RSV Disease

Registered drug

Poland

Participants:0–17 years
Substances:RESPIRATORY SYNCYTIAL VIRUS, SUBGROUP A, STABILIZED PREFUSION F PROTEIN 847A
Sponsor:Pfizer Inc.

Contact Research Centre

Pneumococcal immunisation

Recruiting

Safety and immune response of PF-07872412 compared with 20-valent pneumococcal conjugate vaccine for pneumococcal disease in healthy children and adolescents

Registered drugNo placebo

Safety and immune response of PF-07872412 compared with 20-valent pneumococcal conjugate vaccine for pneumococcal disease in healthy children and adolescents

Registered drugNo placebo

Finland

Participants:0–17 years
Substances:PF-07831695
Sponsor:Pfizer Inc.

Contact Research Centre

Obesity+1

Recruiting

A Phase 3 Study of Once‑Monthly PF‑08653944 vs Placebo for Weight Loss in Adults with Overweight or Obesity

Investigational

A Phase 3 Study of Once‑Monthly PF‑08653944 vs Placebo for Weight Loss in Adults with Overweight or Obesity

Investigational

France

Participants:18–64 years · 65+ years
Substances:Berobenatide
Sponsor:Pfizer Inc.

Contact Research Centre

Non-small cell lung cancer

Recruiting

Phase 2 Study of Safety and Efficacy of PF-08634404 Alone or with Drug Combination in Adults with Early-Stage or Locally Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo

Phase 2 Study of Safety and Efficacy of PF-08634404 Alone or with Drug Combination in Adults with Early-Stage or Locally Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Pfizer Inc.

Contact Research Centre

Pneumococcal immunisation

Recruiting

Safety of PF-07872412 versus 20‑valent pneumococcal conjugate vaccine in healthy infants for prevention of pneumococcal disease

Registered drugNo placebo

Safety of PF-07872412 versus 20‑valent pneumococcal conjugate vaccine in healthy infants for prevention of pneumococcal disease

Registered drugNo placebo

Finland

Participants:0–17 years
Substances:PF-07831695
Sponsor:Pfizer Inc.

Contact Research Centre

Oesophageal adenocarcinoma

Recruiting

Study of PF-08634404 with chemotherapy drug combination in previously untreated patients with locally advanced or metastatic gastric and gastroesophageal adenocarcinoma

Registered drug